43810 Federal Register / Vol. 82, No. 180 / Tuesday, September 19, 2017 / Notices 

I. Background 

The MRB is composed of five medical 

experts who each serve two-year terms. 

Section 4116 of SAFETEA–LU requires 

the Secretary of Transportation, with the 

advice of the MRB and the chief medical 

examiner, to establish, review, and 

revise ‘‘medical standards for operators 

of commercial motor vehicles that will 

ensure that the physical condition of 

operators of commercial motor vehicles 

is adequate to enable them to operate 

the vehicles safely.’’ The MRB operates 

in accordance with FACA under the 

terms of its charter, filed November 25, 

2015. 

On January 15, 2013, FMCSA 

announced in a Notice of Final 

Disposition entitled, Qualification of 

Drivers; Exemption Applications; 

Epilepsy and Seizure Disorders, (78 FR 

3069), its decision to grant requests from 

22 individuals for exemptions from the 

regulatory requirement that interstate 

CMV drivers have ‘‘no established 

medical history or clinical diagnosis of 

epilepsy or any other condition which 

is likely to cause loss of consciousness 

or any loss of ability to control a CMV.’’ 

Since the January 15, 2013, notice, the 

Agency has published additional 

notices granting requests from 

individuals for exemptions from the 

regulatory requirement regarding 

epilepsy found in 49 CFR 391.41(b)(8). 

In reaching the decision to grant 

exemption requests, FMCSA considers 

the 2007 recommendations of the 

Agency’s Medical Expert Panel (MEP). 

The January 15, 2013, Federal Register 

notice (78 FR 3069) provides the current 

MEP recommendations, which is the 

criteria the Agency uses to grant seizure 

exemptions. 

The Agency’s decision regarding 

exemption applications is based on an 

individualized assessment of each 

applicant’s medical information, 

including the following: The root cause 

of the respective seizure(s) and medical 

information about the applicant’s 

seizure history; the length of time that 

has elapsed since the individual’s last 

seizure; the stability of each individual’s 

treatment regimen; and the duration of 

time on or off anti-seizure medication. 

In addition, the Agency reviews the 

treating clinician’s medical opinion 

related to the ability of the driver to 

operate a CMV safely with a history of 

seizure and each applicant’s driving 

record found in the Commercial Driver’s 

License Information System (CDLIS) for 

commercial driver’s license (CDL) 

holders, and interstate and intrastate 

inspections recorded in the Motor 

Carrier Management Information System 

(MCMIS). For non-CDL holders, the 

Agency reviews the driving records 

from the State Driver’s Licensing 

Agencies (SDLAs). 

II. Meeting Participation 

Oral comments from the public will 

be heard during the meeting, at the 

discretion of the Chairman. Members of 

the public may submit written 

comments on the topics to be 

considered during the meeting by 

Wednesday, September 20, to Federal 

Docket Management System (FDMC) 

Docket Number FMCSA–2008–0362 for 

the MRB using any of the following 

methods: 

• Federal eRulemaking Portal: Go to 

http://www.regulations.gov. Follow the 

online instructions for submitting 

comments. 

• Fax: 202–493–2251. 

• Mail: Docket Management Facility; 

U.S. Department of Transportation, 1200 

New Jersey Avenue SE., West Building, 

Room W12–140, Washington, DC 20590. 

• Hand Delivery: U.S. Department of 

Transportation, 1200 New Jersey 

Avenue SE., Room W12–140, 

Washington, DC, between 9 a.m. and 5 

p.m., E.T. Monday through Friday, 

except Federal holidays. 

Issued on: September 13, 2017. 

Larry W. Minor, 

Associate Administrator for Policy. 

[FR Doc. 2017–19906 Filed 9–18–17; 8:45 am] 

BILLING CODE 4910–EX–P 

DEPARTMENT OF TRANSPORTATION 

Federal Motor Carrier Safety 

Administration 

[Docket No. FMCSA–2017–0043] 

Qualification of Drivers; Exemption 

Applications; Diabetes Mellitus 

AGENCY: Federal Motor Carrier Safety 

Administration (FMCSA), DOT. 

ACTION: Notice of applications for 

exemption; request for comments. 

SUMMARY: FMCSA announces receipt of 

applications from 31 individuals for an 

exemption from the prohibition in the 

Federal Motor Carrier Safety 

Regulations (FMCSRs) against persons 

with insulin-treated diabetes mellitus 

(ITDM) operating a commercial motor 

vehicle (CMV) in interstate commerce. If 

granted, the exemptions would enable 

these individuals with ITDM to operate 

CMVs in interstate commerce. 

DATES: Comments must be received on 

or before October 19, 2017. 

ADDRESSES: You may submit comments 

bearing the Federal Docket Management 

System (FDMS) Docket No. FMCSA– 

2017–0043 using any of the following 

methods: 

• Federal eRulemaking Portal: Go to 

http://www.regulations.gov. Follow the 

online instructions for submitting 

comments. 

• Mail: Docket Management Facility; 

U.S. Department of Transportation, 1200 

New Jersey Avenue SE., West Building 

Ground Floor, Room W12–140, 

Washington, DC 20590–0001. 

• Hand Delivery: West Building 

Ground Floor, Room W12–140, 1200 

New Jersey Avenue SE., Washington, 

DC, between 9 a.m. and 5 p.m., e.t., 

Monday through Friday, except Federal 

Holidays. 

• Fax: 1–202–493–2251. 

Instructions: Each submission must 

include the Agency name and the 

docket number(s) for this notice. Note 

that all comments received will be 

posted without change to http://

www.regulations.gov, including any 

personal information provided. Please 

see the Privacy Act heading below for 

further information. 

Docket: For access to the docket to 

read background documents or 

comments, go to http://

www.regulations.gov at any time or 

Room W12–140 on the ground level of 

the West Building, 1200 New Jersey 

Avenue SE., Washington, DC, between 9 

a.m. and 5 p.m., e.t., Monday through 

Friday, except Federal holidays. The 

FDMS is available 24 hours each day 

e.t., 365 days each year. If you want 

acknowledgment that we received your 

comments, please include a selfaddressed, stamped envelope or 

postcard or print the acknowledgement 

page that appears after submitting 

comments online. 

Privacy Act: In accordance with 5 

U.S.C. 553(c), DOT solicits comments 

from the public to better inform its 

rulemaking process. DOT posts these 

comments, without edit, including any 

personal information the commenter 

provides, to http://www.regulations.gov, 

as described in the system of records 

notice (DOT/ALL–14 FDMS), which can 

be reviewed at http://www.dot.gov/ 

privacy. 

FOR FURTHER INFORMATION CONTACT: Ms. 

Christine A. Hydock, Chief, Medical 

Programs Division, (202) 366–4001, 

fmcsamedical@dot.gov, FMCSA, 

Department of Transportation, 1200 

New Jersey Avenue SE., Room W64– 

224, Washington, DC 20590–0001. 

Office hours are 8:30 a.m. to 5 p.m., e.t., 

Monday through Friday, except Federal 

holidays. If you have questions 

regarding viewing or submitting 

material to the docket, contact Docket 

Services, telephone (202) 366–9826. 


asabaliauskas on DSKBBXCHB2PROD with NOTICES
Federal Register / Vol. 82, No. 180 / Tuesday, September 19, 2017 / Notices 43811 

SUPPLEMENTARY INFORMATION: 

I. Background 

Under 49 U.S.C. 31136(e) and 31315, 

FMCSA may grant an exemption from 

the FMCSRs for a two-year period if it 

finds ‘‘such exemption would likely 

achieve a level of safety that is 

equivalent to or greater than the level 

that would be achieved absent such 

exemption.’’ The statute also allows the 

Agency to renew exemptions at the end 

of the two-year period. 

The 31 individuals listed in this 

notice have requested an exemption 

from the diabetes prohibition in 49 CFR 

391.41(b)(3). Accordingly, the Agency 

will evaluate the qualifications of each 

applicant to determine whether granting 

the exemption will achieve the required 

level of safety mandated by statute. 

The physical qualification standard 

for drivers regarding diabetes found in 

49 CFR 391.41(b)(3) states that a person 

is physically qualified to drive a CMV 

if that person: 

Has no established medical history or 

clinical diagnosis of diabetes mellitus 

currently requiring insulin for control. 

The Agency established the current 

requirement for diabetes in 1970 

because several risk studies indicated 

that drivers with diabetes had a higher 

rate of crash involvement than the 

general population. 

FMCSA established its diabetes 

exemption program, based on the 

Agency’s July 2000 study entitled ‘‘A 

Report to Congress on the Feasibility of 

a Program to Qualify Individuals with 

Insulin-Treated Diabetes Mellitus to 

Operate in Interstate Commerce as 

Directed by the Transportation Act for 

the 21st Century.’’ The report concluded 

that a safe and practicable protocol to 

allow some drivers with ITDM to 

operate CMVs is feasible. The 

September 3, 2003 (68 FR 52441), 

Federal Register notice in conjunction 

with the November 8, 2005 (70 FR 

67777), Federal Register notice provides 

the current protocol for allowing such 

drivers to operate CMVs in interstate 

commerce. 

FMCSA notes that section 4129 of the 

Safe, Accountable, Flexible and 

Efficient Transportation Equity Act: A 

Legacy for Users requires the Secretary 

to revise its diabetes exemption program 

established on September 3, 2003 (68 FR 

52441). The revision must provide for 

individual assessment of drivers with 

diabetes mellitus, and be consistent 

with the criteria described in section 

4018 of the Transportation Equity Act 

for the 21st Century (49 U.S.C. 31305). 

Section 4129 requires: (1) Elimination of 

the requirement for three years of 

experience operating CMVs while being 

treated with insulin; and (2) 

establishment of a specified minimum 

period of insulin use to demonstrate 

stable control of diabetes before being 

allowed to operate a CMV. 

In response to section 4129, FMCSA 

made immediate revisions to the 

diabetes exemption program established 

by the September 3, 2003 notice. 

FMCSA discontinued use of the threeyear driving experience and fulfilled the 

requirements of section 4129 while 

continuing to ensure that operation of 

CMVs by drivers with ITDM will 

achieve the requisite level of safety 

required of all exemptions granted 

under 49 U.S.C. 31136(e). 

Section 4129(d) also directed FMCSA 

to ensure that drivers of CMVs with 

ITDM are not held to a higher standard 

than other drivers, with the exception of 

limited operating, monitoring and 

medical requirements that are deemed 

medically necessary. 

The FMCSA concluded that all of the 

operating, monitoring and medical 

requirements set out in the September 3, 

2003, notice, except as modified, were 

in compliance with section 4129(d). 

Therefore, all of the requirements set 

out in the September 3, 2003, notice, 

except as modified by the notice in the 

Federal Register on November 8, 2005 

(70 FR 67777), remain in effect. 

II. Qualifications of Applicants 

Valerian J. Ahles 

Mr. Ahles, 63, has had ITDM since 

2013. His endocrinologist examined him 

in 2017 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Ahles understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Ahles meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His optometrist 

examined him in 2017 and certified that 

he does not have diabetic retinopathy. 

He holds a Class B CDL from Minnesota. 

Gabriel P. Aranda 

Mr. Aranda, 54, has had ITDM since 

2017. His endocrinologist examined him 

in 2017 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Aranda understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Aranda meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His 

ophthalmologist examined him in 2017 

and certified that he does not have 

diabetic retinopathy. He holds a Class A 

CDL from Idaho. 

Herbert M. Boggs, Sr. 

Mr. Boggs, 56, has had ITDM since 

2012. His endocrinologist examined him 

in 2017 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Boggs understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Boggs meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His optometrist 

examined him in 2017 and certified that 

he does not have diabetic retinopathy. 

He holds a Class A CDL from Virginia. 

Samuel D. Chadwick 

Mr. Chadwick, 65, has had ITDM 

since 2015. His endocrinologist 

examined him in 2017 and certified that 

he has had no severe hypoglycemic 

reactions resulting in loss of 

consciousness, requiring the assistance 

of another person, or resulting in 

impaired cognitive function that 

occurred without warning in the past 12 

months and no recurrent (two or more) 

severe hypoglycemic episodes in the 

last five years. His endocrinologist 

certifies that Mr. Chadwick understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Chadwick meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His optometrist 

examined him in 2017 and certified that 

he does not have diabetic retinopathy. 

He holds a Class A CDL from New York. 

Michael J. Coopey 

Mr. Coopey, 56, has had ITDM since 

2015. His endocrinologist examined him 

in 2017 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 


asabaliauskas on DSKBBXCHB2PROD with NOTICES
43812 Federal Register / Vol. 82, No. 180 / Tuesday, September 19, 2017 / Notices 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Coopey understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Coopey meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His optometrist 

examined him in 2017 and certified that 

he does not have diabetic retinopathy. 

He holds a Class B CDL from New 

Jersey. 

David A. Dworak 

Mr. Dworak, 57, has had ITDM since 

2016. His endocrinologist examined him 

in 2017 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Dworak understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Dworak meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His optometrist 

examined him in 2017 and certified that 

he does not have diabetic retinopathy. 

He holds a Class B CDL from Wisconsin. 

Francis G. Gahr 

Mr. Gahr, 60, has had ITDM since 

2017. His endocrinologist examined him 

in 2017 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Gahr understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Gahr meets the requirements 

of the vision standard at 49 CFR 

391.41(b)(10). His optometrist examined 

him in 2017 and certified that he does 

not have diabetic retinopathy. He holds 

an operator’s license from Pennsylvania. 

Robert Giordano 

Mr. Giordano, 57, has had ITDM since 

2010. His endocrinologist examined him 

in 2017 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Giordano understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Giordano meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His optometrist 

examined him in 2017 and certified that 

he does not have diabetic retinopathy. 

He holds an operator’s license from New 

Jersey. 

John W.E. Haddad 

Mr. Haddad, 34, has had ITDM since 

2012. His endocrinologist examined him 

in 2017 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Haddad understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Haddad meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His optometrist 

examined him in 2017 and certified that 

he does not have diabetic retinopathy. 

He holds an operator’s license from 

Virginia. 

Anthony W. Hartley 

Mr. Hartley, 33, has had ITDM since 

2013. His endocrinologist examined him 

in 2017 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Hartley understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Hartley meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His optometrist 

examined him in 2017 and certified that 

he does not have diabetic retinopathy. 

He holds a Class B CDL from Maine. 

Shay S. Hobbs 

Mr. Hobbs, 22, has had ITDM since 

2010. His endocrinologist examined him 

in 2017 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Hobbs understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Hobbs meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His optometrist 

examined him in 2017 and certified that 

he does not have diabetic retinopathy. 

He holds an operator’s license from 

Alabama. 

Jack T. Jaworski 

Mr. Jaworski, 22, has had ITDM since 

2006. His endocrinologist examined him 

in 2017 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Jaworski understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Jaworski meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His optometrist 

examined him in 2017 and certified that 

he does not have diabetic retinopathy. 

He holds an operator’s license from New 

York. 

Mark E. Jernstad 

Mr. Jernstad, 60, has had ITDM since 

2016. His endocrinologist examined him 

in 2017 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Jernstad understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Jernstad meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His optometrist 

examined him in 2017 and certified that 

he does not have diabetic retinopathy. 

He holds a Class A CDL from Illinois. 


asabaliauskas on DSKBBXCHB2PROD with NOTICES
Federal Register / Vol. 82, No. 180 / Tuesday, September 19, 2017 / Notices 43813 

Kenneth F. Julius 

Mr. Julius, 76, has had ITDM since 

2017. His endocrinologist examined him 

in 2017 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Julius understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Julius meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His optometrist 

examined him in 2017 and certified that 

he does not have diabetic retinopathy. 

He holds a Class A CDL from 

Minnesota. 

Timothy D. Kinsey 

Mr. Kinsey, 39, has had ITDM since 

2015. His endocrinologist examined him 

in 2017 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Kinsey understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Kinsey meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His 

ophthalmologist examined him in 2017 

and certified that he does not have 

diabetic retinopathy. He holds an 

operator’s license from South Carolina. 

Fred A. Klein 

Mr. Klein, 60, has had ITDM since 

2012. His endocrinologist examined him 

in 2017 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Klein understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Klein meets the requirements 

of the vision standard at 49 CFR 

391.41(b)(10). His ophthalmologist 

examined him in 2017 and certified that 

he does not have diabetic retinopathy. 

He holds a Class B CDL from Montana. 

Kenneth C. Knighten 

Mr. Knighten, 66, has had ITDM since 

2000. His endocrinologist examined him 

in 2017 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Knighten understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Knighten meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His 

ophthalmologist examined him in 2017 

and certified that he does not have 

diabetic retinopathy. He holds an 

operator’s license from Oregon. 

Thomas R. Ligman 

Mr. Ligman, 63, has had ITDM since 

2016. His endocrinologist examined him 

in 2017 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Ligman understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Ligman meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His optometrist 

examined him in 2017 and certified that 

he does not have diabetic retinopathy. 

He holds an operator’s license from 

Pennsylvania. 

Richard A. Miller 

Mr. Miller, 62, has had ITDM since 

1987. His endocrinologist examined him 

in 2017 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Miller understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Miller meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His 

ophthalmologist examined him in 2017 

and certified that he has stable 

proliferative diabetic retinopathy. He 

holds an operator’s license from 

Pennsylvania. 

Thomas J. Miller, Jr. 

Mr. Miller, 69, has had ITDM since 

2015. His endocrinologist examined him 

in 2017 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Miller understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Miller meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His optometrist 

examined him in 2017 and certified that 

he does not have diabetic retinopathy. 

He holds a Class A CDL from North 

Carolina. 

Danny L. Nelson 

Mr. Nelson, 44, has had ITDM since 

2015. His endocrinologist examined him 

in 2017 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Nelson understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Nelson meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His 

ophthalmologist examined him in 2017 

and certified that he does not have 

diabetic retinopathy. He holds an 

operator’s license from Massachusetts. 

James D. Northum 

Mr. Northum, 61, has had ITDM since 

2005. His endocrinologist examined him 

in 2017 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Northum understands 

diabetes management and monitoring, 


asabaliauskas on DSKBBXCHB2PROD with NOTICES
43814 Federal Register / Vol. 82, No. 180 / Tuesday, September 19, 2017 / Notices 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Northum meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His optometrist 

examined him in 2017 and certified that 

he does not have diabetic retinopathy. 

He holds an operator’s license from 

Texas. 

Everett M. Ortiz 

Mr. Ortiz, 68, has had ITDM since 

2014. His endocrinologist examined him 

in 2017 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Ortiz understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Ortiz meets the requirements 

of the vision standard at 49 CFR 

391.41(b)(10). His ophthalmologist 

examined him in 2017 and certified that 

he does not have diabetic retinopathy. 

He holds an operator’s license from 

Oregon. 

Rodney D. Rexford 

Mr. Rexford, 79, has had ITDM since 

2012. His endocrinologist examined him 

in 2017 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Rexford understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Rexford meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His optometrist 

examined him in 2017 and certified that 

he does not have diabetic retinopathy. 

He holds a Class A CDL from New 

Hampshire. 

Daniel L. Richardson, Sr. 

Mr. Richardson, 66, has had ITDM 

since 2015. His endocrinologist 

examined him in 2017 and certified that 

he has had no severe hypoglycemic 

reactions resulting in loss of 

consciousness, requiring the assistance 

of another person, or resulting in 

impaired cognitive function that 

occurred without warning in the past 12 

months and no recurrent (two or more) 

severe hypoglycemic episodes in the 

last five years. His endocrinologist 

certifies that Mr. Richardson 

understands diabetes management and 

monitoring, has stable control of his 

diabetes using insulin, and is able to 

drive a CMV safely. Mr. Richardson 

meets the requirements of the vision 

standard at 49 CFR 391.41(b)(10). His 

ophthalmologist examined him in 2017 

and certified that he has stable 

nonproliferative diabetic retinopathy. 

He holds a Class A CDL from Maryland. 

Michael K. Richardson 

Mr. Richardson, 58, has had ITDM 

since 2017. His endocrinologist 

examined him in 2017 and certified that 

he has had no severe hypoglycemic 

reactions resulting in loss of 

consciousness, requiring the assistance 

of another person, or resulting in 

impaired cognitive function that 

occurred without warning in the past 12 

months and no recurrent (two or more) 

severe hypoglycemic episodes in the 

last five years. His endocrinologist 

certifies that Mr. Richardson 

understands diabetes management and 

monitoring, has stable control of his 

diabetes using insulin, and is able to 

drive a CMV safely. Mr. Richardson 

meets the requirements of the vision 

standard at 49 CFR 391.41(b)(10). His 

optometrist examined him in 2017 and 

certified that he does not have diabetic 

retinopathy. He holds a Class A CDL 

from South Carolina. 

Eliezer Rivera-Nieves 

Mr. Rivera-Nieves, 53, has had ITDM 

since 2015. His endocrinologist 

examined him in 2017 and certified that 

he has had no severe hypoglycemic 

reactions resulting in loss of 

consciousness, requiring the assistance 

of another person, or resulting in 

impaired cognitive function that 

occurred without warning in the past 12 

months and no recurrent (two or more) 

severe hypoglycemic episodes in the 

last five years. His endocrinologist 

certifies that Mr. Rivera-Nieves 

understands diabetes management and 

monitoring, has stable control of his 

diabetes using insulin, and is able to 

drive a CMV safely. Mr. Rivera-Nieves 

meets the requirements of the vision 

standard at 49 CFR 391.41(b)(10). His 

ophthalmologist examined him in 2017 

and certified that he does not have 

diabetic retinopathy. He holds an 

operator’s license from Connecticut. 

Jacob D. Savage 

Mr. Savage, 34, has had ITDM since 

1996. His endocrinologist examined him 

in 2017 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Savage understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Savage meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His optometrist 

examined him in 2017 and certified that 

he does not have diabetic retinopathy. 

He holds a Class A CDL from Tennessee. 

Jamesha K. Thomas 

Ms. Thomas, 27, has had ITDM since 

1998. Her endocrinologist examined her 

in 2017 and certified that she has had 

no severe hypoglycemic reactions 

resulting in loss of consciousness, 

requiring the assistance of another 

person, or resulting in impaired 

cognitive function that occurred without 

warning in the past 12 months and no 

recurrent (two or more) severe 

hypoglycemic episodes in the last five 

years. Her endocrinologist certifies that 

Ms. Thomas understands diabetes 

management and monitoring has stable 

control of her diabetes using insulin, 

and is able to drive a CMV safely. Ms. 

Thomas meets the requirements of the 

vision standard at 49 CFR 391.41(b)(10). 

Her optometrist examined her in 2017 

and certified that she does not have 

diabetic retinopathy. She holds an 

operator’s license from South Carolina. 

Stephen M. Ward 

Mr. Ward, 67, has had ITDM since 

2014. His endocrinologist examined him 

in 2017 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Ward understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Ward meets the requirements 

of the vision standard at 49 CFR 

391.41(b)(10). His ophthalmologist 

examined him in 2017 and certified that 

he has stable nonproliferative diabetic 

retinopathy. He holds a Class A CDL 

from Massachusetts. 

Robert A. Young 

Mr. Young, 47, has had ITDM since 

2017. His endocrinologist examined him 


asabaliauskas on DSKBBXCHB2PROD with NOTICES
Federal Register / Vol. 82, No. 180 / Tuesday, September 19, 2017 / Notices 43815 

in 2017 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Young understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Young meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His 

ophthalmologist examined him in 2017 

and certified that he has stable 

nonproliferative diabetic retinopathy. 

He holds a Class A CDL from Tennessee. 

III. Request for Comments 

In accordance with 49 U.S.C. 31136(e) 

and 31315, FMCSA requests public 

comment from all interested persons on 

the exemption petitions described in 

this notice. We will consider all 

comments received before the close of 

business on the closing date indicated 

in the date’s section of the notice. 

IV. Submitting Comments 

You may submit your comments and 

material online or by fax, mail, or hand 

delivery, but please use only one of 

these means. FMCSA recommends that 

you include your name and a mailing 

address, an email address, or a phone 

number in the body of your document 

so that FMCSA can contact you if there 

are questions regarding your 

submission. 

To submit your comment online, go to 

http://www.regulations.gov and in the 

search box insert the docket number 

FMCSA–2017–0043 and click the search 

button. When the new screen appears, 

click on the blue ‘‘Comment Now!’’ 

button on the right hand side of the 

page. On the new page, enter 

information required including the 

specific section of this document to 

which each comment applies, and 

provide a reason for each suggestion or 

recommendation. If you submit your 

comments by mail or hand delivery, 

submit them in an unbound format, no 

larger than 81⁄2 by 11 inches, suitable for 

copying and electronic filing. If you 

submit comments by mail and would 

like to know that they reached the 

facility, please enclose a stamped, selfaddressed postcard or envelope. 

We will consider all comments and 

materials received during the comment 

period. FMCSA may issue a final 

determination at any time after the close 

of the comment period. 

V. Viewing Comments and Documents 

To view comments, as well as any 

documents mentioned in this preamble, 

go to http://www.regulations.gov and in 

the search box insert the docket number 

FMCSA–2017–0043 and click ‘‘Search.’’ 

Next, click ‘‘Open Docket Folder’’ and 

you will find all documents and 

comments related to this notice. 

Issued on: September 13, 2017. 

Larry W. Minor, 

Associate Administrator for Policy. 

[FR Doc. 2017–19911 Filed 9–18–17; 8:45 am] 

BILLING CODE 4910–EX–P 

DEPARTMENT OF TRANSPORTATION 

Federal Motor Carrier Safety 

Administration 

[Docket No. FMCSA–2000–7006; FMCSA– 

2001–9258; FMCSA–2001–9561; FMCSA– 

2002–11714; FMCSA–2002–13411; FMCSA– 

2003–14504; FMCSA–2003–15268; FMCSA– 

2004–17984; FMCSA–2005–20560; FMCSA– 

2005–21254; FMCSA–2006–26653; FMCSA– 

2007–2663; FMCSA–2007–27897; FMCSA– 

2008–0266; FMCSA–2009–0086; FMCSA– 

2009–0121; FMCSA–2010–0354; FMCSA– 

2010–0372; FMCSA–2010–0385; FMCSA– 

2011–0010; FMCSA–2011–0024; FMCSA– 

2011–0057; FMCSA–2011–0092; FMCSA– 

2011–0102; FMCSA–2011–0140; FMCSA– 

2011–0141; FMCSA–2013–0021; FMCSA– 

2013–0025; FMCSA–2013–0027; FMCSA– 

2013–0028; FMCSA–2013–0029; FMCSA– 

2014–0002; FMCSA–2014–0010; FMCSA– 

2014–0302; FMCSA–2014–0305; FMCSA– 

2015–0048; FMCSA–2015–0049; FMCSA– 

2015–0052; FMCSA–2015–0053; FMCSA– 

2015–0055] 

Qualification of Drivers; Exemption 

Applications; Vision 

AGENCY: Federal Motor Carrier Safety 

Administration (FMCSA), DOT. 

ACTION: Notice of final disposition. 

SUMMARY: FMCSA announces its 

decision to renew exemptions for 125 

individuals from the vision requirement 

in the Federal Motor Carrier Safety 

Regulations (FMCSRs) for interstate 

commercial motor vehicle (CMV) 

drivers. The exemptions enable these 

individuals to continue to operate CMVs 

in interstate commerce without meeting 

the vision requirement in one eye. 

DATES: Each group of renewed 

exemptions were applicable on the 

dates stated in the discussions below 

and will expire on the dates stated in 

the discussions below. 

FOR FURTHER INFORMATION CONTACT: Ms. 

Christine A. Hydock, Chief, Medical 

Programs Division, 202–366–4001, 

fmcsamedical@dot.gov, FMCSA, 

Department of Transportation, 1200 

New Jersey Avenue SE., Room W64– 

224, Washington, DC 20590–0001. 

Office hours are from 8:30 a.m. to 5 

p.m., e.t., Monday through Friday, 

except Federal holidays. If you have 

questions regarding viewing or 

submitting material to the docket, 

contact Docket Services, telephone (202) 

366–9826. 

SUPPLEMENTARY INFORMATION: 

I. Electronic Access 

You may see all the comments online 

through the Federal Document 

Management System (FDMS) at: http:// 

www.regulations.gov. 

Docket: For access to the docket to 

read background documents or 

comments, go to http//

www.regulations.gov and/or Room 

W12–140 on the ground level of the 

West Building, 1200 New Jersey Avenue 

SE., Washington, DC, between 9 a.m. 

and 5 p.m., e.t., Monday through Friday, 

except Federal holidays. 

Privacy Act: In accordance with 5 

U.S.C. 553(c), DOT solicits comments 

from the public to better inform its 

rulemaking process. DOT posts these 

comments, without edit, including any 

personal information the commenter 

provides, to http://www.regulations.gov, 

as described in the system of records 

notice (DOT/ALL–14 FDMS), which can 

be reviewed at http://www.dot.gov/ 

privacy. 

II. Background 

On July 18, 2017, FMCSA published 

a notice announcing its decision to 

renew exemptions for 125 individuals 

from the vision requirement in 49 CFR 

391.41(b)(10) to operate a CMV in 

interstate commerce and requested 

comments from the public (82 FR 

32919). The public comment period 

ended on August 17, 2017 and no 

comments were received. 

As stated in the previous notice, 

FMCSA has evaluated the eligibility of 

these applicants and determined that 

renewing these exemptions would 

achieve a level of safety equivalent to or 

greater than the level that would be 

achieved by complying with the current 

regulation 49 CFR 391.41(b)(10). 

The physical qualification standard 

for drivers regarding vision found in 49 

CFR 391.41(b)(10) states that a person is 

physically qualified to drive a CMV if 

that person: 

Has distant visual acuity of at least 20/40 

(Snellen) in each eye without corrective 

lenses or visual acuity separately corrected to 

20/40 (Snellen) or better with corrective 

lenses, distant binocular acuity of a least 20/ 

40 (Snellen) in both eyes with or without 

corrective lenses, field of vision of at least 

70° in the horizontal meridian in each eye, 

and the ability to recognize the colors of 


asabaliauskas on DSKBBXCHB2PROD with NOTICES